Axon Enterprise, Inc. (NASDAQ:AXON) Receives $335.27 Average Price Target from Analysts

Axon Enterprise, Inc. (NASDAQ:AXON) has been given a consensus rating of “Moderate Buy” by the twelve ratings firms that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold rating and eleven have issued a buy rating on the company. The average 12 month target price among brokerages that have covered the stock in the last year is $335.27.

A number of research firms have recently commented on AXON. JPMorgan Chase & Co. boosted their price objective on Axon Enterprise from $330.00 to $365.00 and gave the stock an “overweight” rating in a research note on Thursday, April 11th. JMP Securities restated a “market outperform” rating and set a $375.00 price objective on shares of Axon Enterprise in a research report on Tuesday, May 7th. William Blair reiterated an “outperform” rating on shares of Axon Enterprise in a report on Wednesday, April 24th. Robert W. Baird raised their target price on shares of Axon Enterprise from $260.00 to $300.00 and gave the stock an “outperform” rating in a report on Thursday, February 22nd. Finally, StockNews.com lowered shares of Axon Enterprise from a “buy” rating to a “hold” rating in a research report on Thursday, March 14th.

Insiders Place Their Bets

In other news, President Joshua Isner sold 44,000 shares of Axon Enterprise stock in a transaction that occurred on Thursday, May 9th. The shares were sold at an average price of $309.96, for a total value of $13,638,240.00. Following the transaction, the president now owns 275,843 shares of the company’s stock, valued at $85,500,296.28. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, insider Jeffrey C. Kunins sold 43,668 shares of the firm’s stock in a transaction dated Thursday, May 9th. The stock was sold at an average price of $309.94, for a total value of $13,534,459.92. Following the sale, the insider now directly owns 189,719 shares of the company’s stock, valued at $58,801,506.86. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, President Joshua Isner sold 44,000 shares of Axon Enterprise stock in a transaction dated Thursday, May 9th. The stock was sold at an average price of $309.96, for a total value of $13,638,240.00. Following the completion of the transaction, the president now owns 275,843 shares in the company, valued at $85,500,296.28. The disclosure for this sale can be found here. Insiders sold 87,976 shares of company stock valued at $27,268,201 over the last 90 days. 6.10% of the stock is currently owned by company insiders.

Institutional Trading of Axon Enterprise

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Fifth Third Bancorp boosted its position in shares of Axon Enterprise by 50.9% in the third quarter. Fifth Third Bancorp now owns 972 shares of the biotechnology company’s stock valued at $193,000 after acquiring an additional 328 shares during the period. Teacher Retirement System of Texas increased its holdings in shares of Axon Enterprise by 3.9% during the 3rd quarter. Teacher Retirement System of Texas now owns 5,438 shares of the biotechnology company’s stock worth $1,082,000 after purchasing an additional 204 shares during the period. New Mexico Educational Retirement Board increased its holdings in shares of Axon Enterprise by 12.4% during the 3rd quarter. New Mexico Educational Retirement Board now owns 3,636 shares of the biotechnology company’s stock worth $724,000 after purchasing an additional 400 shares during the period. Daiwa Securities Group Inc. increased its holdings in shares of Axon Enterprise by 3.5% during the 3rd quarter. Daiwa Securities Group Inc. now owns 7,365 shares of the biotechnology company’s stock worth $1,466,000 after purchasing an additional 251 shares during the period. Finally, Principal Financial Group Inc. raised its position in shares of Axon Enterprise by 3.6% during the third quarter. Principal Financial Group Inc. now owns 87,012 shares of the biotechnology company’s stock valued at $17,315,000 after buying an additional 3,055 shares during the last quarter. Institutional investors and hedge funds own 79.08% of the company’s stock.

Axon Enterprise Stock Performance

Shares of AXON opened at $285.63 on Monday. The firm has a market capitalization of $21.56 billion, a PE ratio of 83.52 and a beta of 0.91. The company has a quick ratio of 2.55, a current ratio of 2.91 and a debt-to-equity ratio of 0.37. The firm has a 50-day moving average price of $306.23 and a 200 day moving average price of $274.76. Axon Enterprise has a 52-week low of $175.37 and a 52-week high of $329.87.

Axon Enterprise (NASDAQ:AXON) last posted its quarterly earnings data on Friday, May 10th. The biotechnology company reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.95 by $0.20. Axon Enterprise had a net margin of 15.60% and a return on equity of 11.71%. The business had revenue of $460.74 million during the quarter, compared to analysts’ expectations of $441.57 million. During the same period last year, the firm posted $0.51 earnings per share. The business’s revenue was up 34.3% on a year-over-year basis. On average, sell-side analysts anticipate that Axon Enterprise will post 2.35 earnings per share for the current fiscal year.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.